Personal Genome Diagnostics

Executive Summary

Personal Genome Diagnostics (PGDx) is a private oncology diagnostics company headquartered in Baltimore, Maryland. Founded in 2010, PGDx specializes in developing and commercializing comprehensive genomic profiling (CGP) kits and bioinformatics solutions that enable rapid, in-house tumor profiling for precision cancer care. The company's mission is to democratize access to advanced genomic testing by providing distributed, kitted solutions that allow laboratories worldwide to perform tumor profiling without sending samples to central labs. PGDx's product suite includes tissue-based and liquid biopsy assays that cover hundreds of cancer-related genes, facilitating the identification of actionable mutations and matching patients to targeted therapies or clinical trials. The company's approach aims to reduce turnaround times and costs associated with genomic testing, potentially increasing adoption in community hospitals and smaller labs. As a private entity, PGDx does not disclose financials, but its technology platform positions it in the competitive CGP market, competing with larger players like Foundation Medicine and Guardant Health. The company's future growth depends on expanding its test menu, securing regulatory approvals, and forging partnerships with pharmaceutical companies for companion diagnostic development.

Upcoming Catalysts (preview)

• Q3 2026FDA approval or clearance for a new liquid biopsy CGP test60% success
• Q4 2026Strategic partnership with a top-10 pharmaceutical company for companion diagnostic development50% success
• Q1 2027Series D or later-stage financing round to support commercial expansion70% success